Health Care [ 5/12 ] | Biotechnology [ 33/74 ]
NYSE | Common Stock
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.
The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo.
The company was founded in 2018 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 19, 26 | 0.04 Increased by +128.51% | -0.04 Increased by +188.43% |
| Mar 2, 26 | -0.11 Increased by +5.58% | -0.09 Decreased by -22.22% |
| Nov 3, 25 | -0.16 Decreased by -6.67% | -0.17 Increased by +5.88% |
| Aug 7, 25 | -0.17 Decreased by -13.33% | -0.17 |
| May 12, 25 | -0.13 Decreased by -91.43% | -0.12 Decreased by -11.67% |
| Feb 26, 25 | -0.12 Decreased by -94.17% | -0.12 Increased by +2.92% |
| Nov 4, 24 | -0.15 Decreased by -66.67% | -0.13 Decreased by -15.38% |
| Aug 5, 24 | -0.15 Decreased by -66.67% | -0.06 Decreased by -150.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 83.23 M Increased by +2.60 K% | 5.40 M Increased by +110.14% | Increased by +6.48% Increased by +100.38% |
| Dec 31, 25 | 41.87 M Increased by +633.06% | -36.59 M Increased by +25.99% | Decreased by -87.40% Increased by +89.90% |
| Sep 30, 25 | 13.12 M Increased by +1.70 K% | -55.79 M Decreased by -35.38% | Decreased by -425.24% Increased by +92.50% |
| Jun 30, 25 | 4.83 M Increased by +236.79% | -59.01 M Increased by +87.24% | Decreased by -1.22 K% Increased by +96.21% |
| Mar 31, 25 | 3.08 M Increased by +1.07 K% | -53.24 M Decreased by -259.90% | Decreased by -1.73 K% Increased by +69.19% |
| Dec 31, 24 | 5.71 M Increased by +2.06 K% | -49.45 M Decreased by -258.63% | Decreased by -865.79% Increased by +83.42% |
| Sep 30, 24 | 727.00 K Increased by +N/A% | -41.21 M Decreased by -109.73% | Decreased by -5.67 K% Decreased by N/A% |
| Jun 30, 24 | 1.44 M Increased by +N/A% | -462.49 M Decreased by -2.14 K% | Decreased by -32.23 K% Decreased by N/A% |